Skip to main content

Published locations for FOURIER: Evolocumab follow-up shows no cognitive adverse effects

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. FOURIER: Evolocumab follow-up shows no cognitive adverse effects

User login

  • Reset your password
  • /content/fourier-evolocumab-follow-shows-no-cognitive-adverse-effects
  • /familypracticenews/article/221684/lipid-disorders/fourier-evolocumab-follow-shows-no-cognitive
  • /internalmedicinenews/article/221684/lipid-disorders/fourier-evolocumab-follow-shows-no-cognitive
  • /clinicalendocrinologynews/article/221684/lipid-disorders/fourier-evolocumab-follow-shows-no
  • /ecardiologynews/article/221684/lipid-disorders/fourier-evolocumab-follow-shows-no-cognitive-adverse
  • /cardiology/article/221684/lipid-disorders/fourier-evolocumab-follow-shows-no-cognitive-adverse
  • /endocrinology/article/221684/lipid-disorders/fourier-evolocumab-follow-shows-no-cognitive-adverse
  • /internalmedicine/article/221684/lipid-disorders/fourier-evolocumab-follow-shows-no-cognitive-adverse
  • /neurology/article/221684/lipid-disorders/fourier-evolocumab-follow-shows-no-cognitive-adverse
  • /familymedicine/article/221684/lipid-disorders/fourier-evolocumab-follow-shows-no-cognitive-adverse
  • /chestphysician/article/221684/lipid-disorders/fourier-evolocumab-follow-shows-no-cognitive-adverse
  • /clinicalneurologynews/article/221684/lipid-disorders/fourier-evolocumab-follow-shows-no-cognitive